Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Yusuke Higuchi , Takehiro Ogata , Masahiro Nishi , et al Added: 3 years ago
Best Abstract Award – First prize Topic: Heart Failure (Basic), Molecular Cardiology Introduction Heart failure (HF) is a debilitating disease associated with high morbidity and mortality. The high mortality rate reflects inadequacy of modern therapy and calls for new mechanistic treatments. A major cause of HF is the adverse tissue remodelling with fibrosis. Excessive extracellular matrix (ECM… View more

Heart Failure
Compound A, a Ginger Extract, Significantly Reduces Pressure Overload-induced Systolic Heart Failure in Mice
Author(s): Yuto Kawase , Kana Shimizu , Masafumi Funamoto , et al Added: 2 years ago

Heart Failure
The Natural Product Zerumbone Suppresses Pressure Overload-Induced Cardiac Dysfunction by Inhibiting Cardiac Hypertrophy and Fibrosis
Author(s): Mikuto Tojima , Yasufumi Katanasaka , Yoichi Sunagawa , et al Added: 2 years ago

Prevention & Chronic Conditions
The Role of Isocitrate Dehydrogenases in Direct Reprogramming to Cardiomyocytes
Author(s): Tomoaki Ishida , Tomoe Ueyama , Ai Baba , et al Added: 2 years ago

Prevention & Chronic Conditions
Research Area(s) / Expertise:

Cardio-oncology

Heart Failure

 Job title: Assistant Professor
Dr Giselle Melendez is anAssistant Professor atWake Forest University School of Medicine, Winston-Salem, US.Commencing her scientific career at the University of South Carolina School of Medicine, Dr. Melendez focused on molecular mediators of myocardial extracellular matrix remodeling and heart failure. Notably, her research uncovered vital insights into inflammatory cytokines TNF-α, IL-6, and… View more
Author(s): Tomomi Akama , Araya Tenghattakorn , Motoharu Yamasaki , et al Added: 3 years ago
Topic: Heart Failure (Basic), Molecular Cardiology Previous studies, including ours, suggest that tumour repressor p53 is activated during somatic cell reprogramming, and efficiency of induced pluripotent stem cell (iPSC) formation is limited through transactivation of p53 target genes leading to apoptosis and cell cycle arrest. Recent studies revealed non-transcriptional effects of p53 on… View more

Heart Failure
Applications for Induced Pluripotent Stem Cells in Disease Modelling and Drug Development for Heart Diseases
Author(s): Shu Nakao , Dai Ihara , Koji Hasegawa , et al Added: 3 years ago
Induced Pluripotent Stem Cells and Their Potential Applications Induced pluripotent stem cells (iPSCs) are generated from somatic cells, such as skin fibroblasts, by ectopic expression of defined reprogramming factors. Within a few years of the first report of the generation of mouse iPSCs, several laboratories reportedly reproduced these cells using other cell types and species using similar… View more

Vascular Disease and Surgery
Author(s): Antonio J Vallejo-Vaz Added: 3 years ago
Heart Failure – A Major Global Health Problem Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality in developed countries and its burden is progressively increasing.1–4 Coronary artery disease (CAD) and other conditions, such as hypertensive heart disease or diabetes mellitus, are rated among the foremost reasons for morbi-mortality worldwide.1–4 In this context,… View more

Imaging & Diagnostics

Heart Failure
Author(s): Rocio Hinojar , Eike Nagel , Valentina O Puntmann Added: 3 years ago
Myocarditis is difficult to diagnose due to its heterogeneous clinical presentation. Patients often present with nonspecific symptoms and there is no easy-to-use and widely available diagnostic test. Although the clinical manifestations of myocarditis are heterogeneous, up to one-third of cases progress toward dilated cardiomyopathy (DCM).1,2 Myocarditis is a major cause of DCM, which is a… View more

Imaging & Diagnostics

Electrophysiology & Arrhythmia
Author(s): John G Coghlan Added: 3 years ago
The pace of progress in the field of pulmonary arterial hypertension (PAH) continues to be breathtaking. In the past couple of years two new oral agents have been granted licences. Fourteen major international drug trials are underway, many evaluating the role of combination therapies, and at least three agents (simvastatin, imatinib and aviptadil) are undergoing proof of concept studies in… View more

Prevention & Chronic Conditions